Literature DB >> 32227124

Human Immunodeficiency Virus-2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe.

Dirk Berzow1,2, Diane Descamps3,4, Martin Obermeier2,5,6, Charlotte Charpentier3,4, Rolf Kaiser6,7,8,9, Lutz Guertler6,8,10, Josef Eberle6,8,10, Annemarie Wensing11,12, Saleta Sierra7, Jean Ruelle13, Perpetua Gomes14,15, Kamal Mansinho16, Ninon Taylor17, Björn Jensen9,18, Matthias Döring19, Martin Stürmer20, Jürgen Rockstroh11,21, Ricardo Camacho22.   

Abstract

Human immunodeficiency virus-2 (HIV-2) is endemic in some countries in West Africa. Due to the lower prevalence in industrialized countries, there is limited experience and knowledge on the management of individuals living with HIV-2 in Europe. Compared to HIV-1, there are differential characteristics of HIV-2 regarding diagnostic procedures, the clinical course, and, most importantly, antiretroviral therapy. We integrated the published literature on HIV-2 (studies and reports on epidemiology, diagnostics, the clinical course, and treatment), as well as expert experience in diagnosing and clinical care, to provide recommendations for a present standard of medical care of those living with HIV-2 in Western European countries, including an overview of strategies for diagnosis, monitoring, and treatment, with suggestions for effective drug combinations for first- and second-line treatments, post-exposure prophylaxis, and the prevention of mother-to-child transmission, as well as listings of mutations related to HIV-2 drug resistance and C-C motif chemokine receptor type 5 and C-X-C motif chemokine receptor type 4 coreceptor tropism.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV-2; antiretroviral therapy; care; diagnosis; resistance

Year:  2021        PMID: 32227124     DOI: 10.1093/cid/ciaa275

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  2 in total

1.  Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.

Authors:  Robert A Smith; Vincent H Wu; Jennifer Song; Dana N Raugi; Khardiata Diallo Mbaye; Moussa Seydi; Geoffrey S Gottlieb
Journal:  J Infect Dis       Date:  2022-08-26       Impact factor: 7.759

2.  HIV-2: still off the radar for India's 90-90-90 targets.

Authors:  Priyanka Khopkar-Kale; Smita Kulkarni
Journal:  Indian J Med Res       Date:  2021-07       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.